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Lipopolysaccharide is one of the major constituents of the
Gram-negative bacterial outermembrane and is a potent stimula-
tor of the host innate immune response. The biosynthesis of the
lipidAmoiety of lipopolysaccharide is a complex process inwhich
multiple gene products are involved. Two late lipid A acyl trans-
ferases,LpxLandLpxM,were first identified inEscherichiacoliand
showntoberesponsible for theadditionof secondaryacyl chains to
the2and3positionsof lipidA, respectively.Here,wedescribe the
identification of two lpxLhomologues in the genomeofBordetella
pertussis. We show that one of them, LpxL2, is responsible for the
addition of the secondarymyristate group that is normally present
at the 2 position of B. pertussis lipid A, whereas the other one,
LpxL1,mediates theadditionofapreviouslyunrecognizedsecond-
ary 2-hydroxy laurate at the 2 position. Increased expression of
lpxL1 results in the appearance of a hexa-acylated lipopolysaccha-
ride form with strongly increased endotoxic activity. In addition,
we show that an lpxL1-deficient mutant of B. pertussis displays a
defect in the infection of humanmacrophages.
Pertussis or whooping cough is a severe acute respiratory
illness that is characterized by paroxysmal coughing and a dis-
tinctive “whooping” sound when air is subsequently inhaled.
The disease is highly contagious and most severe in neonates
and children younger than one year. Pertussis is caused by the
Gram-negative bacteriumBordetella pertussis.While the genus
Bordetella currently encompasses nine species, apart from B.
pertussis only three other members, Bordetella bronchiseptica,
Bordetella parapertussis, and Bordetella holmesii, have been
associated with respiratory infections in humans and other
mammals (1). The Gram-negative bacterial cell envelope is
composed of two membranes, the inner and the outer mem-
brane, which are separated by the periplasm. The inner mem-
brane is a symmetrical bilayer composed of phospholipids,
whereas the outer membrane is asymmetric and consists of
phospholipids in the inner leaflet and lipopolysaccharide
(LPS)2 in the outer leaflet. LPS, which is also known as endo-
toxin, consists of three distinct structural domains: lipid A, the
core, and theO-antigen (2). The first domain, lipid A, functions
as a hydrophobic membrane anchor and forms the bioactive
component of the molecule (3). The structure of lipid A is con-
served among different bacterial groups, indicating its impor-
tance for the correct functioning of the outer membrane. Gen-
erally, lipid A consists of a -1,6-linked D-glucosamine (GlcN)
disaccharide carrying ester- and amide-linked 3-hydroxyl fatty
acids at the C-2, C-3, C-2, and C-3 positions, and phosphate
groups at positions C-1 and C-4. The endotoxic activity of LPS
is based on the recognition of lipid A by the TLR4/MD-2 com-
plex of the host, which leads to the activation of NF-B and,
consequently, to an increased production and secretion of pro-
inflammatory cytokines, such as IL-6, tumor necrosis factor-,
and IL-1 (4).
Current knowledge about lipid A biosynthesis is mainly
derived from studies in Escherichia coli and Salmonella
enterica serovar Typhimurium (Salmonella typhimurium),
where the biosynthetic pathway has been completely eluci-
dated. It consists of nine enzymes that work in a successive
order. In the first step, an acyl chain is transferred from the
R-3-hydroxytetradecanoic acid (3OHC14)-acyl carrier protein
to the GlcN 3 position of UDP-N-acetyl glucosamine (GlcNAc)
by the acyltransferase LpxA (5, 6). Then, the acylated UDP-
GlcNAc is de-acetylated by the LpxC enzyme (7), after which
LpxD adds a 3-hydroxyl acyl chain at this position (8), resulting
in a UDP-2,3-diacylGlcN molecule. Next, UMP is removed
from a proportion of the UDP-2,3-diacylGlcN pool by LpxH
(9), before a tetra-acylated GlcN disaccharide is formed by
LpxB (5). After 4-phosphorylation by LpxK, creating a mole-
cule known as lipid IVA (10), two 2-keto-3-deoxyoctulosonic
acid residues are added by KdtA (11), and finally the secondary
acyl chains are added by the late acyltransferases LpxL and
LpxM (12, 13).
The late acyltransferase LpxL of E. coli was found to be
responsible for the addition of a secondary laurate (C12)moiety
to the 2 position of lipid A (12, 14). LpxL homologues have
been identified in several otherGram-negative bacteria, includ-
ingHaemophilus influenzae (15),Neisseriameningitidis (16), S.
typhimurium (17), and Yersinia pestis (18). The second late
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acyltransferase, LpxM, is closely related to LpxL and was ini-
tially described as a multicopy suppressor of an lpxLmutation
(19). InE. coli, LpxM is responsible for the addition of a second-
ary myristate (C14) chain at the 3 position of lipid A (13).
Bacteria with mutations in lpxL and lpxM harbor underacy-
lated LPS species, which display a reduced activity in stimulat-
ing innate immune responses (16, 20–21).
The structure of B. pertussis lipid A (Fig. 1) resembles that of
E. coli. It typically consists of a GlcN disaccharide substituted
with 3OH C14 residues at positions 2, 2, and 3 via ester or
amide linkage and with an R-3-hydroxydecanoic acid (3OH
C10) residue at the 3 position via ester linkage. A secondaryC14
replaces the hydroxyl group of 3OHC14 at the 2 position (Fig.
1) (22). Limited information on the genetics of Bordetella lipid
A biosynthesis is currently available, and detailed analyses have
only been performed for the acyl transferase LpxA and the
2-keto-3-deoxyoctulosonic acid transferase KdtA (23, 24).
The goal of the present study was to identify the gene encod-
ing the enzyme responsible for the attachment of the secondary
acyl chain toB. pertussisLPSwith the eventual goal to inactivate
this gene and create a less reactogenic vaccine strain. We iden-
tified a locus of two lpxL homologues in the genome of B. per-
tussis, which raised the questionwhich of these genes is respon-
sible for the attachment of the single secondary acyl chain and
what the function of the other LpxL homologue might be. The
study resulted in the identification of new LPS forms in B. per-
tussis, required for successful infection of humanmacrophages.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions—All bacterial
strains used are described in Table 1. Typically, the E. coli
strains were grown at 37 °C in a modified Luria-Bertani broth,
designatedLB (25), supplementedwith 0.2%glucose or at either
30 °C or 42 °C in a synthetic minimal medium (26) supple-
mented with 0.5% glucose, while shaking at 200 rpm. When
appropriate, the media were supplemented with 100 g/ml
ampicillin, 10 g/ml tetracycline, 10 g/ml gentamicin, 50
g/ml nalidixic acid, or 300 g/ml streptomycin, for plasmid
maintenance or strain selection. B. pertussiswas grown at 35 °C
on Bordet-Gengou (BG) agar (Difco) supplemented with 15%
defibrinated sheep blood (Biotrading). To induce the expres-
sion of the lpxL1 and lpxL2 genes from plasmids in B. pertussis,
the bacteria were grown in synthetic THIJS medium (27) sup-
plemented with 1 mM isopropyl-1-thio--D-galactopyranoside
at 35 °C while shaking at 175 rpm.
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FIGURE 1. B. pertussis lipid A architecture. B. pertussis lipid A consists of a
bisphosphorylated GlcN disaccharide substituted with three R-3-hydroxytet-
radecanoic acidmoieties andoneR-3-hydroxydecanoic acidmoiety, ofwhich
the 2 fatty-acyl chain is esterified with myristate (22).
TABLE 1
Bacterial strains and plasmids
Strain or plasmid Genotype or descriptiona Source or referenceb
B. pertussis
B213 StrR derivative of B. pertussis strain Tohama (41)
B213 lpxL1 lpxL1 mutant of B213 strain, StrR, GmR This study
E. coli
TOP10F F{lacIq Tn10 (TetR)} mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74
deoR recA1 araD139 (ara-leu)7697 galU galK rpsL endA1 nupG Invitrogen
DH5 F, (lacZYA-algF)U169 thi-1 hsdR17 gyrA96 recA1 endA1 supE44 relA1
phoA 80 dlacZM15 (42)
SM10pir thi thr leu fhuA lacY supE recA::RP4-2-Tc::Mu pir R6K KanR NVI
W3110 Wild-type strain, F,  NVI
MLK53 lpxL::Tn10, TetR derivative of W3110 (19)
Plasmids
pCRII-TOPO E. coli cloning vector, AmpR KanR Invitrogen
pET-11a E. coli high copy expression vector, AmpR, T7 promoter Novagen
pMMB67EH Broad host range expression vector, AmpR (43)
pKAS32 Allelic exchange suicide vector, AmpR (44)
pBSL141 E. coli vector harboring gentamicin-resistance cassette, AmpR GmR (45)
pLpxL1 pET-11a derivative harboring B. pertussis lpxL1 This study
pLpxL2 pET-11a derivative harboring B. pertussis lpxL2 This study
pMMB67EH-LpxL1 pMMB67EH derivative harboring B. pertussis lpxL1 This study
pMMB67EH-LpxL2 pMMB67EH derivative harboring B. pertussis lpxL2 This study
pCRII-LpxL1up pCRII derivative harboring lpxL1-upstream sequence This study
pCRII-LpxL1down pCRII derivative harboring lpxL1-downstream sequence This study
pKAS32-LpxL1KO pKAS32 derivative harboring lpxL1 knockout construct, AmpR, GmR This study
a Str, streptomycin; Gm, gentamicin; Tet, tetracycline; Amp, ampicillin; Kan, kanamycin.
bNVI, Netherlands Vaccine Institute, Bilthoven, The Netherlands.
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Recombinant DNA Techniques—All plasmids used are
described in Table 1. Plasmid DNA was isolated using the Pro-
mega WizardPlus Minipreps system. Calf-intestine alkaline
phosphatase and restriction endonucleases were used accord-
ing to the instructions of the manufacturer (Fermentas). DNA
fragments were isolated from agarose gels using the Qiagen
quick gel extraction kit. Ligations were performed using the
rapid DNA ligation kit (Roche Applied Science).
The lpxL1 and lpxL2 genes fromB. pertussis strain B213were
obtained by PCR. The chromosomal template DNA was pre-
pared by resuspending109 bacteria in 50l of distilled water,
after which the suspension was heated for 15 min at 95 °C. The
suspension was then centrifuged for 1 min at 16,100 g, after
which the supernatant was used as template DNA. The
sequences of the forward primers, which contained anNdeI site
(underlined), including an ATG start codon, were 5-AACAT-
ATGCTCGTCACCCTGTTA-3 (lpxL1) and 5-AACATAT-
GAGCCAATTCAAGA-3 (lpxL2). The sequences of the
reverse primers, which contained a BamHI site (underlined)
and included a stop codon, were 5-AAGGATCCTCATCGT-
TCGGGTTCCTG-3 (lpxL1) and 5-AAGGATCCTCAGTA-
CAGCTTGGGCTT-3 (lpxL2). The PCRs were performed
under the following condition: 50 l of total reaction volume,
25 pmol of each primer, 0.2 mM dNTPs, 3 l of template DNA
solution, 1.5% dimethyl sulfoxide, and 1.75 units of Expand
High Fidelity enzymemix with buffer supplied by themanufac-
turer (Roche Applied Science). The temperature program was
as follows: 95 °C for 3 min, a cycle of 1 min at 95 °C, 1 min at
60 °C, and 2min at 72 °C, repeated 30 times, followed by 10min
at 72 °C and subsequent cooling to 4 °C. The PCR products
were purified from agarose gel and subsequently cloned into
pCRII-TOPO. Plasmid DNA from a correct clone was digested
with NdeI and BamHI, and the LpxL-encoding fragments were
ligated into NdeI- and BamHI-digested pET-11a. The ligation
mixture was used to transform E. coli DH5 using the CaCl2
method (28). Plasmids containing the correct inserts were des-
ignated pLpxL1 and pLpxL2. The nucleotide sequences of the
cloned genes were confirmed by sequencing in both directions.
To allow for expression in B. pertussis, the lpxL1 and lpxL2
geneswere subcloned into the broad host range, low copy num-
ber vector pMMB67EH. To this end, pLpxL1 and pLpxL2 were
digested with XbaI and HindIII, and the relevant fragments
were ligated into XbaI- andHindIII-digested pMMB67EH. The
ligation mixture was used to transform E. coli DH5. Plasmids
with the correct inserts were designated pMMB67EH-LpxL1
and pMMB67EH-LpxL2 (Table 1). The pMMB67EH-based
plasmids were used to transform E. coli SM10(pir), which
allowed for subsequent transfer of the plasmids to B. pertussis
by conjugation. For complementation experiments, E. coli
strainsW3110 andMLK53 (Table 1)were transformedwith the
plasmids.
To construct a B. pertussis lpxL1mutant strain, we ampli-
fied a part of the DNA upstream of lpxL1 from B. pertussis
strain B213 by using primers 5-AAATTCGCTCTGGCGC-
TGCAC-3 and 5-AATCAGCACGCGTCTGACCGATGC-
GAATGAAAGGGCGG-3, containing an MluI site (under-
lined). Additionally, a DNA fragment downstream of lpxL1was
obtained by PCR with primers 5-AAGTCAGACGCGTGCT-
GAGACAGCGCGCGGCAGGAACC-3, containing an MluI
site (underlined), and 5-AATCCACGTGATAGCGCCC-
GGT-3. Both PCR products were cloned into pCRII-TOPO,
resulting in plasmids pCRII-LpxL1up and pCRII-LpxL1down,
respectively. An MluI-XbaI fragment of pCRII-LpxL1down was
ligated into MluI-XbaI-restricted pCRII-LpxL1up. The result-
ing plasmid was cut with MluI to allow for insertion of the
gentamicin resistance cassette from plasmid pBSL141 obtained
by MluI digestion. Finally, an XbaI-SacI fragment of the con-
struct obtained was ligated into the XbaI-SacI-restricted sui-
cide plasmid pKAS32. The final construct, designated pKAS32-
LpxL1KO, contained the gentamicin resistance cassette in the
reverse orientation relative to the transcription direction of the
lpxL1 gene and was used to construct a B. pertussis lpxL1
mutant by allelic exchange. Transformants were screened by
PCR using various primer sets.
Isolation andAnalysis of LPS—LPSwas isolated using the hot
phenol/water extraction method (29) with slight modifications
(30). The fatty acid compositionwas analyzed using a 6890Agi-
lent gas chromatograph (31). The lipid A moiety of LPS was
isolated as described (30) and used for structural analysis by
nanoelectrospray tandem mass spectrometry (MS/MS) on a
Finnigan LCQ in the negative (MS) or positive (MS/MS) ion
mode (32).
Stimulation of Macrophages and IL-6 Quantification—The
humanmacrophage cell lineMonoMac 6 (MM6) (33)was stim-
ulated with serial dilutions of whole bacterial cell suspensions
or purified LPS as described (30). The bacterial cell suspensions
were prepared by collecting the cells from cultures by centrifu-
gation, after which they were resuspended in phosphate-buff-
ered saline at an optical density at 590 nm (A590) of 1.0, heat-
inactivated for 10 min in the presence of 8 mM formaldehyde,
and stored at 4 °C. Following stimulation, IL-6 concentrations
in the culture supernatants were quantified with an enzyme-
linked immunosorbent assay against human IL-6 according to
the manufacturer’s instructions (PeliKine CompactTM).
Infection of Human Macrophages—For infection of human
macrophages, bacteria were grown for 16 h on fresh BG blood
agar plates, after which theywerewashed oncewith phosphate-
buffered saline and resuspended in 1 ml of Iscove’s modified
Dulbecco’s medium (Invitrogen). Bacteria were added to 5 
105 MM6 cells, which were maintained in 0.25 ml of pre-
warmed Iscove’smodifiedDulbecco’smedium in 24-well tissue
culture plates, at amultiplicity of infection of 10 (final volume
500 l). After 2 h of incubation (5% CO2 and 37 °C), 100 g/ml
colistin sulfate (end concentration) was added to thewells, after
which the plates were incubated further for 2 h at 37 °C. Then,
the MM6 cells were collected by centrifugation and washed
twice with Iscove’s modified Dulbecco’s medium, after which
they were lysed (1 min at 22 °C) in 0.15 ml of phosphate-buff-
ered saline containing 0.1% Triton X-100. The lysed cells were
plated onto BG blood agar plates, and the number of viable
intracellular bacteriawas estimated by determining the number
of colony forming units (CFUs) after 72 h of growth. Infection
experiments were repeated three times. The colistin sensitivity of
thewild-type andmutant strainwas determined by growing them
in the presence of various concentrations of colistin and, after
Analysis of B. pertussis LpxL Homologues
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diluting the suspensionsandplating themonBGbloodagarplates,
counting the number of CFUs.
Association of B. pertussis to Human Macrophages—Associ-
ation of bacteria toMM6 cells was evaluated by flow cytometry.
2  109 bacteria were labeled by incubation with 50 g of flu-
orescein isothiocyanate in 1 ml of 50 mM carbonate/bicarbon-
ate buffer (pH 9.6) at room temperature for 20 min. The fluo-
rescein isothiocyanate-labeled bacteria were thenwashed twice
withTSA (20mMTris-HCl (pH7.5), 150mMNaCl, 1mMCaCl2,
2 mM MgCl2, 0.5% human serum albumin (w/v) (Sigma)), pas-
saged through a 5-m filter (Millipore) for declumping, and
resuspended in TSA to an absorbance at 600 nm of 1. Associa-
tion to macrophages was assessed in TSA buffer by incubating
(45 min at 37 °C or 4 °C) the fluorescein isothiocyanate-labeled
bacteria with the macrophages (multiplicity of infection 2, 10,
and 50) and, after washing the cells, measuring the percentage
of fluorescently labeled macrophages in FL1 by flow cytometry
(FACScan, BD Biosciences).
Statistical Analysis—Data were statistically analyzed using
two-way analysis of variance followed by Bonferroni’s multiple
comparison test (GraphPad). Alternatively, a Student’s t test
(two-tailed, two-sample unequal variance) was used. Differ-
ences were considered to be significant when p 0.05.
RESULTS
Identification of Late Lipid A Acyltransferase Homologues in
B. pertussis—The 306- and 323-amino acid residue sequences
of the E. coli K-12 LpxL and LpxM proteins with GenBankTM
accession numbers NP_415572 and NP_416369, respectively,
were used to identify putative lpxL and lpxM homologues in
the complete B. pertussis genome sequence present in the
NCBI data base (www.ncbi.nlm.nih.gov/sutils/genom_table.cgi).
BLAST search (34) revealed the presence of two homologues of
lpxL and lpxM, i.e.BP3072 andBP3073withGenBankTMacces-
sion numbers NP_881643 and NP_881644, respectively.
BP3072 and BP3073 show sequence identities of 21 and 29% to
E. coliLpxM, respectively, of 23 and 31% toE. coliLpxL, respec-
tively, and of 25% to each other. Because both proteins show a
higher sequence identity to E. coli LpxL than to E. coli LpxM,
BP3072 and BP3073 were designated lpxL1 and lpxL2, respec-
tively. The open reading frames are adjacent to one another,
with the stop codon of lpxL1 overlapping with the start codon
of lpxL2, and, therefore, seem to form an operon. Upstream, in
the reverse orientation, and downstream of the operon, genes
are located putatively encoding a homologue of the S-adenosyl-
methionine synthetase MetK and of the diaminopimelate epi-
merase DapF, respectively. Further BLAST analysis revealed
the presence of lpxL1 and lpxL2 homologues in B. parapertus-
sis, i.e. BPP0191 and BPP0190 with GenBankTM accession
numbers NP_882552 and NP_882551, respectively, and in B.
bronchiseptica, i.e. BB0194 and BB0193 with GenBankTM
accession numbers NP_886744 and NP_886743, respectively.
The mutual sequence identity between the Bordetella proteins
is 97% for the LpxL1 proteins and 98% for the LpxL2 proteins.
Furthermore, the genetic organization of the lpxL1/lpxL2
operon is conserved among the Bordetella strains.
Cloning of lpxL Genes and Complementation of the E. coli
lpxL Mutant Phenotype—E. coli lpxL mutants show a growth
defect on nutrient broth above 32 °C (14). To test whether the
identified B. pertussis lpxL homologues can complement this
phenotype, we cloned the lpxL1 and lpxL2 genes into the broad
host range, low copy number vector pMMB67EH under the
control of the tac promoter and used the resulting plasmids to
transform E. coli lpxL mutant strain MLK53 (19). As controls,
both MLK53 and the parental E. coli strain W3110 were trans-
formed with vector pMMB67EH. The strains were first grown
to early log phase in synthetic minimal medium at 30 °C, after
which the bacteria were transferred to LB and further incu-
bated at 42 °C. The growth defect of the E. coli lpxLmutant was
complemented by the plasmid harboring lpxL2 (Fig. 2). The
plasmid encoding LpxL1 did not complement the phenotype
and its presence, as compared with the empty vector control,
seemed to hamper growth even further.
Overexpression of lpxL1 and lpxL2 in B. pertussis—The effect
on LPS composition of lpxL1 and lpxL2 overexpression was
studied in B. pertussis strain B213 after introduction of the
pMMB67EH-derived plasmids. No obvious effect of lpxL1 and
lpxL2 overexpression was observed upon Tricine-SDS-PAGE
analysis of isolated LPS (data not shown). To evaluate possible
alterations in LPS composition in more detail, the lipid A moi-
eties of the strains were analyzed by MS in the negative-ion
mode. This analysis revealed the presence of two major lipid A
species in wild-type LPS (Fig. 3A). The peak atm/z 1557 repre-
sents the characteristic penta-acylated bis-phosphate species
that is typically found in B. pertussis (22), whereas the peak at
m/z 1477 corresponds to a penta-acylated mono-phosphate
species. Besides these two major lipid A species, several minor
species were detected. The two peaks at m/z 1307 and 1251
represent deacylated lipid A species of themolecular ion atm/z
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FIGURE 2. Complementation of the temperature-sensitive growth phe-
notype of E. coli lpxL mutant MLK53. Bacteria were grown to early log
phase in synthetic minimal medium at 30 °C. After 3.5 h, the bacteria were
transferred to LB and further incubated at 42 °C. WT, wild-type E. coli strain
W3110 harboring the empty pMMB67EH vector; MLK53, E. coli lpxL mutant
strain harboring the empty pMMB67EH vector; LpxL1, E. coliMLK53 express-
ingB. pertussis lpxL1; LpxL2, E. coliMLK53expressingB. pertussis lpxL2. Absorb-
ance was measured at 600 nm. The experiment was performed in triplicate
(error bars show the standard deviation). A representative result of two inde-
pendent experiments is shown.
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1477 that miss the primary 3OHC10 residue at the 3 position
and a primary 3OH C14 residue, probably at the 3 position
(30), respectively. Additional minor species included molec-
ular ions at m/z 1449 and 1505. Mass calculations indicate
that these species most likely correspond to the molecular
ions at m/z 1251 and 1307, substituted with an additional
hydroxyl C12 chain (m/z 198). The peak at m/z 1718 repre-
sents lipid A modified with hexosamine.3
Upon overexpression of lpxL1 (Fig. 3B), clear changes in the
spectrum of lipid A species were seen. The new lipid A species
detectedwere peaks atm/z 1676 and 1755,which appeared only
after overexpression of lpxL1 (Fig. 3B). Themass of these peaks
corresponds to the molecular ions at m/z 1477 and 1557,
respectively, substitutedwith an additional hydroxyl C12 chain.
No obvious differences were observed upon lpxL2 overexpres-
sion (Fig. 3C).
To determine the location of the additional hydroxyl C12
chain in the ion atm/z 1676, it was subjected toMS/MS analysis
in the positive ion mode. As shown in Fig. 4A, colliding the ion
resulted in multiple fragmentation ions, including ones at m/z
904 and 756. These two ions derive from the non-reducing and
the reducing half of the lipid A molecule, respectively, with the
latter one carrying the additional hydroxyl C12 at either the 2 or
the 3 position. This was confirmed by performing the same
MS/MS analysis on the wild-type penta-acylated ion at m/z
1557, which resulted in corresponding ions atm/z 904 and 558,
i.e. no hydroxyl C12 at the reducing half (Fig. 4B). To discrim-
inate between the presence of theC12 hydroxyl chain at the 2 or
the 3 position, LPS isolated from the lpxL1-overexpressing
strain was subjected to in vitro 3-O-deacylation using purified
recombinant PagL enzyme from Pseudomonas aeruginosa as
described previously (35). MS analysis revealed that 3-O-deac-
ylated lipid A species still carried hydroxyl C12moieties, which
unequivocally showed that the hydroxyl C12 acyl chain was
present at the 2 position (result not shown). Finally, the fatty
acid content of the isolated LPS was analyzed by gas chroma-
tography. The results revealed that LPS from the lpxL1-overex-
pressing strain contained, in contrast to the LPS isolated from
the wild-type and lpxL2-overexpressing strain, 2-hydroxyl
dodecanoic acid (2OH C12), whereas all strains contained
minor, but similar amounts of 3-hydroxyl dodecanoic acid
(3OH C12) (Fig. 5). The presence of minor amounts of 3OH
3 J. Geurtsen, M. Dzieciatkowska, L. Steeghs, J. Boleij, K. Boren, G. Akkerman,
H. J. Hamstra, J. Li, J. Richards, J. Tommassen, andP. vander Ley,manuscript
in preparation.
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FIGURE 3. Structural analysis byMS of purified B. pertussis LPS. Lipid A species fromwild-type B. pertussis strain B213 (A) and its derivatives overexpressing
lpxL1 (B), lpxL2 (C), or deficient for lpxL1 (D) were analyzed byMS. Peaks atm/z 1557, 1477, 1307, and 1251were interpreted as the characteristic penta-acylated
bisphosphate species that is typically found in B. pertussis, the corresponding penta-acylated monophosphate species, the deacylated lipid A species of the
molecular ion atm/z 1477missing the primary 3OH C10 residue at the 3 position, and the deacylated lipid A species of the molecular ion atm/z 1477missing
a primary 3OH C14 residue, respectively. The peaks atm/z 1449, 1505, 1676, and 1755 correspond to the molecular ions present atm/z 1251, 1307, 1477, and
1557, but containing an extra hydroxyl C12 group (m/z 198).
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C12 in wild-type B. pertussis LPS can be explained by the
relaxed acyl chain specificity of the B. pertussis LpxA enzyme
(23). Overall, these data show that overexpression of lpxL1
leads to the specific incorporation of 2OH C12 into B. per-
tussis lipid A and that this moiety is located at the 2 position
(Fig. 4C).
Endotoxic Activity of LPS and Whole Bacterial Cells—To
determine whether lpxL1 or lpxL2 overexpression affected
the endotoxic activity of the LPS, the potency of the purified
LPS to stimulate the production of IL-6 by the human mac-
rophage cell line MM6 was tested (Fig. 6). As compared with
wild-type LPS, the purified LPS from the strain overexpress-
ing lpxL1 had a strongly increased potency to stimulate the
macrophages, as can be expected from its increased amount
of hexa-acyl lipid A (Fig. 6A). Similarly, whole cell suspen-
sions of B. pertussis cells overexpressing lpxL1 showed, as
compared with B. pertussis cells containing the empty vec-
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FIGURE 5. Gas chromatographic analysis of LPS from wild-type, lpxL1-,
and lpxL2-overexpressing B. pertussis strains. LPS purified fromwild-type
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tor, an increased potency to stimulate the macrophages (Fig.
6B). Consistent with the MS data, which did not reveal an
altered LPS composition, overexpression of lpxL2 did not
significantly alter the endotoxic activity of the LPS or whole
bacterial cells.
Construction and Phenotype of a B. pertussis lpxL1 Mutant
Strain—One of our initial aims was to create B. pertussis
mutant strains with less reactogenic LPS. To achieve this goal,
we made several plasmid constructs that were suitable for
replacing the lpxL genes on the B. pertussis chromosome by an
antibiotic resistance cassette via allelic exchange. Following this
strategy, we easily obtained clones in which the lpxL1 gene was
replaced by a gentamicin resistance marker. However, this was
not the case for lpxL2 or the entire lpxL1/lpxL2 operon. We
have tried various strategies, using different constructs, differ-
ent markers, and different selection temperatures, but up till
now, we have not been able to iso-
late a viable lpxL2 or lpxL1/lpxL2 B.
pertussismutant.
To characterize the lpxL1mutant
obtained, we first studied its growth
characteristics. At both 35 °C and at
28 °C, the growth of the mutant
strain in synthetic THIJS medium
was comparable to that of the
wild-type strain (data not shown).
Additionally,Western blots showed
that the expression of the virulence
factors pertactin, fimbriae, pertussis
toxin, and filamentous hemaggluti-
nin was unaffected in the mutant
strain (data not shown). For struc-
tural analysis, LPSwas isolated from
the mutant strain and analyzed by
MS (Fig. 3D). The obtained spec-
trum showed that the LPS content
of the lpxL1-deficient mutant was
highly comparable to that of the
wild-type strain. Interestingly, the
spectrum of the mutant strain still
contained peaks at m/z 1449 and
1505, suggesting that these ions rep-
resent 3OH C12-substituted and
not 2OH C12-substituted LPS spe-
cies. In addition, two novel LPS spe-
cies, at m/z 1267 and 1347, respec-
tively, were present. These peaks
most likely correspond to the
molecular ions at m/z 1477 and
1557, respectively, but without the
secondary C14 chain. The presence
of these two additional peaks sug-
gests that inactivation of lpxL1 leads
to a slightly reduced lpxL2 expres-
sion, possibly by a polar effect of the
gentamicin resistance marker. We
also tested whether the mutant
strain would have a decreased
capability of inducing the production of pro-inflammatory
cytokines, because overexpression of lpxL1 led to increased
stimulatory activity (Fig. 6). However, this was not the case (Fig.
6). All data presented above suggest that under the growth con-
ditions here applied lpxL1 is not expressed, which could mean
that lpxL1 expression is only beneficial for the bacterium under
certain conditions.
Impaired Infection of HumanMacrophages by the B. pertussis
lpxL1 Mutant Strain—B. pertussis is capable of invading and
surviving within various eukaryotic cell types, including human
macrophages (36). In a previous study, it was shown that an
lpxMmutant of Neisseria gonorrhoeae was impaired in its sur-
vival inside urethral epithelial cells (37). To test whether the B.
pertussis lpxL1mutant is affected in its ability to infect human
macrophages, we determined the number of bacteria that could
be recovered from the intracellular compartment after 2 h of
1
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FIGURE 6. IL-6 induction by purified B. pertussis LPS and whole cells. The production of IL-6 by the human
macrophage cell line MM6 was stimulated with serial dilutions of stock solutions of LPS purified from a wild-
type (WT), an lpxL1- or lpxL2-overexpressing, or an lpxL1-deficient (LpxL1 KO) B. pertussis strain (A), or a whole
cell suspensionofB. pertussis cells deficient for lpxL1 (LpxL1KO), overexpressing lpxL1or lpxL2, or containing the
empty vector pMMB67EH (WT) (B). IL-6 concentrations in the culture supernatant were quantified in an
enzyme-linked immunosorbent assay against human IL-6. The data represent the averages of three individual
experiments (error bars show the standard deviation).
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infection. However, we first tested whether the wild-type and
mutant strain were similar in their ability to survive within
medium and in their direct sensitivity to colistin; indeed, no
differences in these respects were observed (data not shown).
As compared with the wild-type strain (2381 	 92 CFU/well),
the number of bacteria recovered for the lpxL1 mutant strain
was
15-fold lower (138	 62CFU/well) (p 0.0001) (Fig. 7A).
Thus, apparently, the activity of LpxL1 is required for the effi-
cient infection of humanmacrophages byB. pertussis. To deter-
mine whether the decreased infectivity of the LpxL1-deficient
strain is due to an abrogated association of the bacteria with the
macrophages, we performed a flow cytometric assay in which
we assessed the wild-type and the LpxL1-deficient strains for
their capacity to associate with themacrophages at either 37 °C
(Fig. 7B) or at 4 °C (Fig. 7C). At both temperatures, the LpxL1-
deficient strain showed an increased, rather than a decreased
association to the macrophages, thus excluding the possibility
that the differences in infectivity are due to a reduced associa-
tion of the mutant with the macrophages. Therefore, the lpxL1
mutant is probably deficient in intracellular survival.
DISCUSSION
B. pertussis lipid A has been reported to consist of penta-
acylated lipid A species containing four primary hydroxylated
acyl chains and one secondary acyl chain, i.e. a C14 acyl chain at
the 2 position (22). The goal of this study was to identify and
characterize the enzyme responsible for the addition of the sec-
ondary C14 acyl chain. BLAST searches using the E. coli late
acyl transferases LpxL and LpxM as leads identified two homo-
logues in the B. pertussis chromosome. This finding raised the
questions which of the two lpxL homologues in B. pertussis
mediates the addition of the secondary C14 chain to the LPS
and what the function of the other lpxL homologue might be.
We found that LpxL2, but not LpxL1, was capable of fully
restoring the temperature-sensitive phenotype of an E. coli
lpxLmutant, indicating that the function of B. pertussis LpxL2
resembles that of E. coli LpxL, and, thus, that LpxL2 mediates
the addition of the secondary C14 acyl chain to the 2 position
ofB. pertussis lipidA. This conclusionwas further supported by
mass spectrometry and endotoxic activity data, which showed
that lpxL2 overexpression in B. pertussis did not lead to signif-
icant changes in the composition or toxicity of the LPS. Because
already 100% of the B. pertussis lipid A species contain a sec-
ondary C14 acyl chain at the 2 position, overexpression of the
responsible enzyme was not expected to affect LPS structure or
toxicity. The observation that LpxL1 was unable to comple-
ment the E. coli lpxL mutant phenotype was a first indication
that LpxL1 has a different function. We showed that lpxL1
overexpression in B. pertussis leads to the accumulation of a
novel, previously undetected lipid A species in B. pertussis con-
taining an extra secondary 2OH C12 chain at the 2 position.
Thus, either LpxL1 functions as a 2-hydroxyl lauryl transferase,
which directly attaches a 2OH C12 moiety to lipid A, or, alter-
natively, as a regular lauryl transferase, which adds a C12 acyl
chain that is later on hydroxylated by a another enzyme, for
instance LpxO, for which a homologue has been found in the B.
pertussis genome (38). Another question is why lpxL1 expres-
sion in E. coli MLK53 did not restore the mutant phenotype,
because it is known that overexpression of a lipid A-acyl trans-
ferase with a different specificity than LpxL, such as LpxM, can
also restore themutant phenotype (19). Possible answers to this
question are that lpxL1 expression in E. coli was not high
enough to support complementation, that LpxL1 functions
only after a secondary acyl chain has been attached to the 2
position, which is not the case in the E. coli lpxLmutant LPS, or
that the acyl chain donorwas not sufficiently present. The latter
possibility is probably only true when LpxL1 indeed directly
transfers a 2OH C12 chain.
In the wild-type B. pertussis strain, all lipid A species found
were secondary acylated with C14, and no species substituted
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FIGURE 7. A, infection of human macrophages by B. pertussis wild-type and
lpxL1mutant strains. Human macrophage cell line MM6 was infected for 2 h
with the B. pertussis wild-type (WT) or lpxL1 mutant (LpxL1 KO) strain. The
number of bacteria recovered from the intracellular compartment after kill-
ing of remaining extracellular bacteria was determined by CFU counting. The
data represent the averages of three individual experiments. B and C, associ-
ation of wild-type B. pertussis (WT) and B. pertussis cells deficient for lpxL1
(LpxL1 KO) with humanmacrophage cell lineMM6. Fluorescently labeledbac-
teria were incubated with the macrophages at 37 °C (B) or 4 °C (C), and bac-
terial association was evaluated by flow cytometry. The numbers along the
x-axis represent the multiplicity of infection; the percentage of fluorescently
labeled cells is shown on the y-axis. The experiment was performed in tripli-
cate. A representative result of two independent experiments is shown. Error
bars show standard deviations, and asterisksmark significant differences (p
0.05).
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with secondary 2OH C12 groups were found. Although
hydroxylated C12-substituted species were present (Fig. 3A,
peaks atm/z 1449 and 1505), we demonstrated, by showing that
these peaks were also present in the LPS from the lpxL1-defi-
cient strain, that theymost likely correspond to lipid A forms in
which the primary 3OH C10 acyl chain or one of the primary
3OH C14 acyl chains is substituted by 3OH C12. These forms
must constitute the source of the minor amounts of 3OH C12
detected by gas chromatography in the LPS of all strains (Fig. 5).
Thus, apparently, under the growth conditions here applied,
LpxL1 activity in the wild-type strain was absent, whereas
LpxL2 was highly active. Because lpxL1 and lpxL2 almost cer-
tainly constitute an operon, this raises an important question as
to how the bacterium is capable of controlling LpxL1 activity.
One possibility is that lpxL1 and lpxL2 expression is differen-
tially controlled at the level of translation initiation. Analysis of
the nucleotide sequence upstream of the ATG start codons of
lpxL1 and lpxL2 supports this hypothesis. The lpxL2 start
codon is preceded by a sequence, -13AGGAAC8-, that
resembles the consensus Shine-Dalgarno sequence -AGG-
AGG-. However, upstream of lpxL1, such a Shine-Dalgarno
sequence could not be found. Also analysis of the 18 to 18
nucleotides around the ATG start codon applying the algo-
rithm described by Kolaskar and Reddy (39), revealed that the
lpxL1ATG start codon is inadequate. Thus, the absence of lipid
A species carrying a 2OH C12 in wild-type B. pertussismay be
explained by a poor translation initiation of lpxL1mRNA.
One of our initial goals was to obtain B. pertussismutants in
which the lpxL homologues, either separately, or as the com-
plete operon, were knocked out. Because mutations in late acyl
transferases have often been shown to reduce the toxicity of the
LPS, we reasoned that B. pertussis lpxL mutant strains may
form a good basis for the development of less reactogenicwhole
cell pertussis vaccines. The only viable mutant obtained was an
lpxL1 knockout. Because we were not able to isolate lpxL2 or
lpxL1/lpxL2 mutants, lpxL2 appears essential for B. pertussis
viability.
Analysis of the lpxL1 mutant strain did not reveal obvious
differences as compared with the wild-type strain with respect
to its growth characteristics, virulence factor expression profile,
endotoxic activity, or LPS content, again indicating that lpxL1,
under standard laboratory conditions, is not expressed. This
situation is probably beneficial for the bacterium, because the
hexa-acylated LPS species, as we showed for the LPS from the
lpxL1-overexpressing strain (Fig. 6A), is highly active and
would rapidly activate the host innate immune system and
thereby evoke clearance of the bacterium. However, it is known
that B. pertussis also has a partial intracellular life cycle (40).
Inside a cell, a bacterium encounters a completely different
environment, which implicates that the requirements to sur-
vive may also be different. It was previously shown that a late
acyl transferasemutant ofN. gonorrhoeae displayed a decreased
survival inside urethral epithelial cells (37). In addition, Gib-
bons et al. (38) proposed a model in which lipid A-2-hydroxy-
lation functions in the suppression of host cell signaling, per-
mitting a more prolonged survival of bacteria in the host cell.
Therefore, we hypothesized that the presence of an extra sec-
ondary 2OH acyl chain may be important during infection of
eukaryotic cells by B. pertussis. Indeed, we showed that the
recovery rate of the lpxL1 mutant strain was much lower than
that of the wild-type strain after infection of human macro-
phages. This was not due to a decreased association of the
mutant strain to the macrophages, because analysis by flow
cytometry showed that themutant cells associated significantly
better to the macrophages than did the wild-type strain. The
reason for this increased association remains unknownbutmay
reflect alterations in the LPS core domain, which could influ-
ence lectin-mediated adherence of the bacteria to the macro-
phages. Overall, our results suggest that the activity of LpxL1 is
indeed required for an efficient infection of human macro-
phages andmay therefore form an important factor for success-
ful host infection by B. pertussis.
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